ICS/LABA Combination
Pregnancy: Compatible — continued use preferred over poor asthma control in pregnancy
Fluticasone-Salmeterol
Brand names: Seretide, AirFluSal
Adult dose
Dose: Seretide 125/25 mcg or 250/25 mcg: 1–2 puffs BD. Accuhaler 250/50 or 500/50: 1 puff BD
Route: Inhaled
Frequency: Twice daily
Max: Fluticasone 1000 mcg/day + salmeterol 100 mcg/day
For persistent asthma and COPD (Gold 3/4). Use lowest effective ICS dose. Not for acute bronchospasm.
Paediatric dose
Route: Inhaled MDI with spacer
Frequency: BD
Max: Fluticasone 100 mcg BD in children ≥4 years
Seretide 50/25 mcg in children ≥4 years; always use spacer device in children
Dose adjustments
Renal
No dose adjustment required
Hepatic
Caution in severe hepatic impairment — increased systemic fluticasone exposure
Clinical pearls
- Always prescribe ICS/LABA together — LABA monotherapy in asthma increases mortality risk
- Rinse mouth and gargle after each use to prevent oral candidiasis
- SMART therapy (single inhaler maintenance and reliever) is preferred in asthma guidelines — use budesonide-formoterol instead
- Seretide cannot be used as SMART therapy — salmeterol is not suitable for reliever use
Contraindications
- Use as monotherapy in asthma (LABA without ICS)
- Hypersensitivity to lactose or milk proteins (Accuhaler)
Side effects
- Oral candidiasis (rinse mouth after use)
- Hoarseness
- Dysphonia
- Paradoxical bronchospasm (rare)
- HPA axis suppression with high doses
- Tachycardia (salmeterol)
Interactions
- Beta-blockers — may antagonise salmeterol bronchodilation
- QT-prolonging drugs — salmeterol increases QT risk
- Strong CYP3A4 inhibitors (ketoconazole) — increase fluticasone exposure
Monitoring
- Peak flow/spirometry
- Signs of oral candidiasis
- Adrenal function if high doses long-term
- Growth in children (high-dose ICS)
Reference: BNFc; BNF; GINA Guidelines 2024; NICE NG80. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024